Deepa Prasad Sells 3,806 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) Stock

Design Therapeutics, Inc. (NASDAQ:DSGN) Director Deepa Prasad sold 3,806 shares of the stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $6.27, for a total transaction of $23,863.62. Following the transaction, the director now owns 20,000 shares in the company, valued at approximately $125,400. This represents a 15.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Design Therapeutics Price Performance

Shares of NASDAQ DSGN opened at $6.25 on Friday. The business has a fifty day moving average price of $5.90 and a 200 day moving average price of $4.98. Design Therapeutics, Inc. has a 1-year low of $2.24 and a 1-year high of $7.77. The stock has a market capitalization of $353.88 million, a P/E ratio of -7.35 and a beta of 1.86.

Institutional Trading of Design Therapeutics

A number of institutional investors have recently modified their holdings of DSGN. Paloma Partners Management Co purchased a new stake in shares of Design Therapeutics during the 3rd quarter valued at $64,000. SG Americas Securities LLC acquired a new stake in Design Therapeutics during the third quarter worth about $66,000. American Century Companies Inc. acquired a new stake in shares of Design Therapeutics during the 2nd quarter worth approximately $71,000. The Manufacturers Life Insurance Company acquired a new stake in Design Therapeutics during the third quarter valued at $71,000. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Design Therapeutics by 75.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 23,497 shares of the company’s stock valued at $79,000 after purchasing an additional 10,113 shares in the last quarter. 56.64% of the stock is currently owned by institutional investors.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.